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Sepsis is one of the leading causes of death worldwide. While the management of critically ill patients with sepsis is certainly better
now compared to 20 years ago, sepsis-associated mortality remains unacceptably high. Annual deaths from sepsis in both children
and adults far surpass the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Given the substantial toll
that sepsis takes worldwide, prevention of sepsis remains a global priority. Multiple eﬀective prevention strategies exist. Antibiotic
prophylaxis, immunizations, and healthcare quality improvement initiatives are important means through which we may reduce
the morbidity and mortality from sepsis around the world. Inclusion of these strategies in a coordinated and thoughtful campaign
to reduce the global burden of sepsis is necessary for the improvement of pediatric health worldwide.
1.Introduction
According to the National Center for Health Statistics and
the Centers for Disease Control and Prevention, sepsis was
the 10th leading cause of death in the United States overall in
2007 [1]. There are between 77 to 240 new cases of sepsis per
100,000 population each year [2, 3]. More importantly, sev-
eral experts believe that the incidence of sepsis will continue
to increase by approximately 1.5% every year, resulting in an
additional 1 million cases per year by 2020 [2, 4, 5]. Several
factors are believed to be responsible for this increase. The
population is growing older, and patients are living longer,
even in the face of diseases that were previously considered
universally fatal. Hospitalized patients are becoming more
dependent upon the use of invasive devices and technology,
all of which are associated with increased risk of infection.
In addition, the epidemiology of sepsis is changing as an-
other consequence of the greater use of invasive devices and
technologyinhospitalizedpatients.Classically,thesepatients
died from gram-negative sepsis. However, infections with
gram-positive bacteria and Candida species are now becom-
ing more prevalent. The number of cases of fungal sepsis,
which is associated with markedly worse outcomes, has in-
creasedbymorethan200percentbetween1979and2000[2].
Clearly, fungal sepsis is becoming an increasingly important
entity and deserves further attention.
The story in children is fairly similar. There are between
20,000 and 42,000 cases of severe sepsis every year in the
United States alone, half of which occur in children with
underlying diseases like cancer and congenital heart disease
[6, 7]. Again, similar to the situation in adults, the incidence
of sepsis in critically ill children is expected to increase as
more children survive diseases that were previously consid-
ered uniformly fatal [8]. While studies on the changing epi-
demiologyofsepsisarefarfromconclusive,theincreaseduti-
lization of invasive devices and the longer survival rates from
diseasessuchascancerwhichwerepreviouslyuniformlyfatal
will likely lead to an increased incidence of invasive Candida
infections and other opportunistic infections.2 Critical Care Research and Practice
Whilethemanagementofcriticallyillpatientswithsepsis
is certainly better now compared to 20 years ago [9–11], sep-
sis-associated mortality remains unacceptably high. Annual
deaths from sepsis in both children and adults far surpass the
number of deaths from acute myocardial infarction (AMI),
stroke, or cancer [4]. Recent estimates suggest that there are
approximately 4,500 children who die every year from sepsis
in the United States alone [6, 12]. The actual number of
deaths associated with sepsis is likely to be much higher, as
many patients usually die from sepsis during the course of
an underlying disease, such as prematurity, congenital heart
disease, or cancer. In many of these cases, deaths are fre-
quently attributed to the underlying disease process, rather
than to sepsis [4, 6, 13, 14]. Therefore, the impact of sepsis
both in terms of annual healthcare costs and attributable
mortality is likely to be greatly underestimated.
Pediatric sepsis is a growing public health problem in
the developing world as well. According to data from the
World Health Organization (WHO), the United Nations
Children’s Fund (UNICEF), and the Bill and Melinda Gates
Foundation, nearly 70% of the 8 million deaths in children
<5yearsofagewereduetoinfectiousdiseases,suchasmalar-
ia, dengue fever, pneumonia, inﬂuenza, and AIDS [15]. As
sepsisistheﬁnalcommonpathwayinmost,ifnotall,ofthese
diseases, sepsis can and should be considered the no. 1 killer
of children worldwide!
Unfortunately, sepsis consistently receives markedly low-
er amounts of research dollars from the National Institutes
of Health compared to the other leading causes of death in
the United States. Surprisingly, sepsis receives less research
fundingcomparedtosmallpox[16],adiseasewhichhasbeen
reportedly “wiped oﬀ the face of the Earth” [17]. Moreover,
sepsis receives relatively little attention in the lay public—
most of the public has never even heard of the term “sepsis”
[18]. Unfortunately, knowledge about sepsis as a disease
entity amongst health care workers is not much better [19–
21]. A recent international survey of over 1,058 physicians
from a wide variety of disciplines, including critical care
medicine, found that nearly two-thirds of the physicians
surveyed believed that a common deﬁnition for sepsis was
lacking [19].
Several promising therapies in preclinical models of
sepsis have universally failed to live up to initial expectations
in subsequent clinical trials in both critically ill children and
adults [11]. In fact, to date, there have been only three posi-
tive clinical trials in critically ill adults with sepsis–early goal-
directedtherapy(EGDT)[22],activatedproteinC(drotreco-
gin alfa, Xigris, Eli Lilly and Co, Indianapolis, IN) [23],
and afelimomab, a monoclonal antibody F(ab’)2 fragment
directed against tumor necrosis factor (TNF)-α [24]. With
theonepossibleexceptionofearlygoal-directedtherapy[25–
30],noneofthesetherapieshaveprovensuccessfulincritical-
ly ill children. Moreover, Eli Lilly and Company recently
announced that it was withdrawing drotrecogin alfa (Xigris)
from the market after the drug failed to improve patient sur-
vivalinarecentlyconcludedprospective,placebo-controlled,
multicenter trial in Europe (Prowess-Shock study) [31].
Given all of these factors, we believe that a new approach
to pediatric sepsis research and public policy is necessary,
perhaps modeled on the successful public health and policy
campaign to reduce mortality from acute myocardial infarc-
tion(AMI),currentlytheleadingcauseofdeathintheUnited
States [10]. The care of patients with AMI has beneﬁted
greatly from worldwide media attention, an unprecedented
level of research funding, and extensive resources directed
towards prevention and management, all of which have re-
sulted in a greater quality of care and a subsequent reduction
in AMI-related mortality. A similar approach can and should
be directed towards improving the quality of care of critically
ill patients with sepsis. Perhaps more importantly, however,
any eﬀort to reduce morbidity and mortality from sepsis
around the globe must include the expanded use of preven-
tion strategies. Multiple prevention strategies have already
proven invaluable in decreasing the incidence of sepsis
worldwide. Herein, we will highlight some of the prevention
strategies with the best supportive evidence, including an-
tibiotic prophylaxis, immunizations, and healthcare quality
improvement initiatives. We believe that the ﬁrst step to-
wards the successful management of critically ill patients
with sepsis is the primary prevention of sepsis itself.
2.AntibioticProphylaxis
Antibiotic prophylaxis has been instrumental in eﬀorts to
decrease the incidence of sepsis in multiple diﬀerent set-
tings. Prophylaxis reduces the risk of sepsis from group B
Streptococcus in neonates, from encapsulated organisms in
patients with asplenia, and from subacute bacterial endocar-
ditis in individuals with structural heart disease (Table 1).
Each of these interventions is vital for the prevention of
overwhelminginfectionforitsrespectivepopulation.Wewill
focus particularly on the prevention of invasive group B
Streptococcus (GBS) infection as a powerful example of how
antibiotic prophylaxis can prevent sepsis.
2.1.GBS:PreventingSepsiswithAntibioticProphylaxis. Inthe
past two decades, intrapartum antibiotic chemoprophylaxis
hassubstantiallyreducedtheincidenceofneonatalsepsisdue
to GBS, from nearly 2 cases per 1,000 live births to less than
0.5 cases per 1000 live births [32]. Prevention of neonatal
GBS infection is important because the infection results in
death and devastating morbidity for a substantial number
of children worldwide. Early neonatal infection from GBS is
vertically transmitted, often presents within the ﬁrst hours of
life and most commonly within the ﬁrst forty-eight hours of
life, and is characterized by rapid clinical deterioration [32].
During the early 1970s in the United States, the mortality
ratesfromearlyneonatalGBSsepsiswere50%orhigherwith
subsequent advances in neonatal medical care reducing the
m o r t a l i t yr a t e st o4t o6p e r c e n t[ 32]. Long-term morbidity
from early neonatal GBS infection, however, includes some
degree of neurologic deﬁcit in approximately half of infected
children and severe neurologic sequelae in nearly one-third
of infected children [32]. Reduction in the burden of early
neonatal GBS sepsis through antibiotic prophylaxis has
therefore been a signiﬁcant achievement.
The evolution of routine antibiotic prophylaxis for ne-
onatal GBS required more than two decades of eﬀorts byCritical Care Research and Practice 3
Table 1: Conditions for which antibiotic prophylaxis is recommended [42].
Prosthetic cardiac valve or prosthetic material used for cardiac valve repair
Previous infective endocarditis
Cardiac transplantation recipients who develop cardiac valvulopathy
Congenital heart disease
(i) Unrepaired cyanotic CHD, including palliative shunts and conduits
(ii) Completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by catheter intervention,
during the ﬁrst 6 months after the procedure
(iii) Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device (which inhibit
endothelialization)
dedicated community of health professionals. In the United
States,themedicalcommunityrecognizedGBSastheleading
infectious cause of early neonatal morbidity and mortality
in the 1970s [33]. Clinical research then revealed that use
of intrapartum antibiotics in women at risk of transmitting
GBS to their children prevented invasive infection in the
ﬁrst week of life [33]. In the 1990s, the American College
of Obstetricians and Gynecologists (ACOG), the Centers for
Disease Control and Prevention (CDC), and the American
Academy of Pediatrics (AAP) recommended intrapartum
prophylaxis for the prevention of early neonatal GBS disease
[33].
The adoption of universal screening for maternal GBS at
35 to 37 weeks gestation followed by recommended antibi-
otic prophylaxis during labor to colonized women has trans-
lated to a substantial decline in the incidence of early neona-
tal GBS disease [33]. Prior to active prevention, incidence of
neonatal GBS disease in the United States was approximately
7,500 cases per year [33]. Since the initiation of prevention
through prophylaxis, the incidence of invasive early GBS
disease has declined approximately by 80% [33]. Rates of
clinical sepsis demonstrate a continuous decline throughout
the 1990s and into the 2000s with a striking decline among
term infants in the two years following the issuance of the
1997 GBS prevention guidelines [33]. Overall, in the United
States, the incidence has declined from 1.7 cases per 1000 live
births in the preprevention era to less than 0.4 cases per 1000
live births after the reissuance of guidelines in 2002 [32, 33].
Though antibiotic prophylaxis clearly prevents over-
whelming infection, the medical community has needed to
examine potential concerns around prophylaxis and its ef-
fects. One concern is that widespread use of antibiotics for
prophylaxis may lead to the development of antibiotic resis-
tance. With respect to prophylaxis for GBS, developing resis-
tance has not been a problem. GBS continues to be sus-
ceptible to penicillin, ampicillin, and ﬁrst-generation ceph-
alosporins, though GBS isolates with increasing minimum
inhibitory concentrations to penicillin and ampicillin have
been observed [33].
Another concern has been that prophylactic antibiotic
use may alter the presentation of illness if infection occurs
in spite of prophylaxis. If this alteration delays recognition
of the disease, it may interfere with the optimal management
of infection. Fortunately, this has not occurred with neonatal
GBS. Since the guidelines were published in 1996, multiple
studies have demonstrated no signiﬁcant diﬀerence in the
clinical presentation of neonates with early GBS disease be-
tween those who have been exposed to intrapartum antibi-
otics and those who have not been exposed [33]. Though
there are concerns to be aware of when using antibiotic pro-
phylaxis, in the case of GBS, antibiotic prophylaxis has not
created these undesired eﬀects.
Nevertheless, antibiotic prophylaxis remains imperfect.
For example, prophylaxis has not aﬀected rates of maternal
colonization with GBS. Despite decades of routine prophy-
laxis, colonization rates for GBS remain unchanged, which
therefore means that risk of neonatal exposure to GBS re-
mains unchanged [33]. Moreover, due to false negative re-
sults, universal screening fails to identify a percentage of
pregnant women colonized with GBS and thereby fails to
protectthechildrenborntothosewomen[33].Thoughthere
are inherent shortcomings to prophylaxis as a prevention
strategy, there also appear to be imperfections in how pro-
phylaxis is realized. In the case of neonatal GBS, impor-
tant disparities remain. While the incidence of early GBS
infection has declined among all racial groups in the United
States, early onset GBS continues to aﬀect African American
children disproportionately, even after adjustments for high-
er preterm delivery rates [32].
Inspiteoftheprogressmadebyintrapartumprophylaxis,
GBS remains the leading cause of early neonatal morbidity
and mortality [32]. As a result, researchers have been inves-
tigating maternal immunization against GBS as a potentially
better strategy in the prevention of neonatal sepsis. Maternal
immunization could reduce colonization rates, provide pro-
tectionagainstoverwhelminginfectionthroughtransplacen-
tal antibody transfer, and ultimately preclude the need for
universalscreeningandprophylaxis [32,33].Forotherinfec-
tions, immunization has already proven to be an essential
tool for prevention eﬀorts.
3. Immunizations
Eﬀectiveimmunizationprogramspreventsepsis.Thoughthe
development of an immunization against GBS has proven
challenging, immunization has successfully mitigated other
causes of overwhelming infection. In fact, infections with
HaemophilusinﬂuenzaetypeB(HIB)andStreptococcuspneu-
moniae, the leading causes of bacterial meningitis, pneu-
monia, and overwhelming infection in children are now4 Critical Care Research and Practice
virtually 100% preventable through immunization [34]. Im-
munization is such a powerful tool against sepsis that adop-
tion of underutilized or new immunizations worldwide by
national immunization programs has been deemed essential
to any eﬀorts to reduce child mortality [35]. The case of HIB
immunization provides a clear example.
3.1. HIB: Preventing Sepsis through Immunization. HIB leads
to at least 3 million cases of severe disease and nearly 400,000
deaths every year [36]. The most concerning manifestations
of HIB infection, including pneumonia, meningitis, and
other life-threatening invasive infections, occur principally
in infants and children less than two years of age [36]. In the
United States, children less than ﬁve years of age account for
morethan85%ofchildrenwhosuﬀerfrominvasiveHIBdis-
ease, and bacteremia represents the majority of invasive dis-
ease [37]. Though HIB disease occurs throughout the world,
the burden of disease remains more predominantly in na-
tions with poorer resources [36]. Typical invasive HIB dis-
eases include not only bacteremia and meningitis but also
pneumonia, epiglottitis, cellulitis, and osteoarticular infec-
tions [36, 38]. In unimmunized populations, invasive HIB
remainsaprominentcauseofbacterialmeningitisininfancy,
and HIB meningitis results in death in up to 20% of infected
persons in spite of appropriate antibiotic management [36].
HIB infection is a formidable disease with considerable mor-
talityandmorbidity,butprimarypreventionthroughimmu-
nization has proven eﬀective.
The conjugate immunization against HIB has prevented
morbidity and mortality from HIB infection so successfully
that the production of the vaccine has been regarded as one
of the signiﬁcant public health advances of the last century
[38]. Through direct and herd eﬀects, immunization against
HIB has changed the epidemiology of HIB disease. Before
immunization against HIB, the nasopharynx of most non-
immunechildrenwascolonizedwithHIB.Whileonlyasmall
percentage of HIB carriers manifest clinical disease, HIB car-
riersarecriticaldisseminatorsofthebacteria[36].Inpopula-
tions with high rates of HIB immunization, nasopharyngeal
colonization rates are considerably lower [36]. More impor-
tantly, research has shown that HIB immunization reduces
substantially the incidence of HIB infection in both immu-
nizedpeopleandinchildrentooyoungtoreceiveHIBimmu-
nization [38].
In fact, the sizeable burden of HIB disease worldwide
is almost entirely preventable through immunization. Cur-
rently, most HIB-related morbidity and mortality occur in
developing nations where invasive HIB disease remains a
substantial public health concern and where population-
wide HIB immunization programs have not yet been em-
ployed [36]. Immunization remains the most eﬀective tool
against invasive HIB disease in both developed and develop-
ing nations. Near elimination of serious HIB disease occurs
within years in most nations that introduce HIB immuniza-
tion into their national immunization programs [36]. As a
result, the World Health Organization (WHO) recommends
that the conjugate HIB vaccine should be included in all
infant immunization programs with the ﬁrst immunization
occurring as soon after six weeks of age as possible [36].
The use of HIB immunization has expanded in the last
ten years. In 2004, only thirteen low-income nations rou-
tinely utilized HIB immunization, but four years later, in
2008, 66 low-income nations had implemented routine HIB
immunization [39]. Similarly, in 2000, the only areas with
widespread implementation of HIB immunization were in
Europe and the Americas, but by 2006, 108 nations, with
more than 55% of the world’s children, had employed HIB
immunization [39]. Now, nearly two-thirds of all childhood
HIB deaths occur in merely ten nations in Africa and
Asia [39]. This expansion of HIB immunization has been
achieved through work by organizations such as WHO and
theGAVIAlliancethatseektoexpandsuppliesofHIBimmu-
nization, to reduce the cost of immunization, and to aid
nations with the introduction of the immunization [35].
Despite the proven value of immunizations, the recommen-
dations of organizations such as WHO, and the eﬀorts of
organizations such as the GAVI Alliance, many low-income
and middle-income nations have not yet adopted routine
HIB immunization [35]. Further expansion of HIB immu-
nization could further decrease childhood morbidity and
mortality worldwide.
HIB provides an enlightening example of the great utility
ofimmunization.Yet,immunizationshaveproventoprevent
sepsis and other serious invasive infections from organisms
other than HIB. Two other vaccine-preventable infections
thatcausesubstantialmorbidity andmortalityinclude Strep-
tococcus pneumoniae and Neisseria meningitides (meningo-
coccus). We will visit brieﬂy these two infections.
3.2. Streptococcus pneumoniae. Streptococcus pneumoniae is
one of the primary causes of sepsis and other serious invasive
diseases among young children and children in low-income
nations[40].Itmayberesponsibleforasmanyasonemillion
childhood deaths every year [40]! Moreover, antibiotic resis-
tance of pneumococci has been increasing, a reality that fur-
ther inspires an increase in the use of prevention strategies
[40]. Meanwhile, immunization with the pneumococcal
conjugate vaccine (PCV) has been shown to prevent over-
whelming pneumococcal infection. As a result, PCV is now
recommended for use in routine immunization programs
[40]. Of note, however, recent research has revealed that
though the rate of hospitalization for pneumonia in children
has decreased following the introduction of PCV, the preva-
lence of empyema, a concerning complication of a small per-
centage of pneumonia hospitalizations, has increased con-
siderably since the start of routine PCV immunization [41].
Nevertheless, further expansion of this immunization could
substantially reduce the incidence of overwhelming infection
from Streptococcus pneumoniae and thereby reduce pediatric
mortality and morbidity worldwide.
3.3. Meningococcus. WHO also recommends that national
childhood immunization programs include the conjugate
vaccine against Neisseria meningitides. Meningococcus is a
bacteria associated with a high rate of morbidity and mortal-
ity due to the sudden onset and rapid progression of infec-
tion, particularly in adolescent populations [43]. Multiple
meningococcal immunizations exist. In the United States,Critical Care Research and Practice 5
Table 2: Key elements in the CCHMC CA-BSI insertion and maintenance bundles.
Insertion bundle
(1) Strict hand hygiene
(2) Full sterile barrier precautions
(a) Catheter insertion training for all credentialed providers
(b) Fully stocked insertion bin/cart
(c) Sterile gown, hat, mask, gloves worn by provider inserting the line
(d) Large sterile drape covering 80–100% of the patient and bed
(3) Chlorhexidine skin scrub at insertion site (2 minute scrub, 1 minute air-dry)
(4) Chlorhexidine-impregnated sponge placed at insertion site
(5) Insertion checklist
(6) Staﬀ empowerment to stop procedure, if necessary
Maintenance bundle
(1) Strict hand hygiene
(a) Hand washing or use of an alcohol-based hand gel by all personnel prior to any catheter care
(b) Wear gloves for all catheter manipulations, medication administration, and so forth
(2) Catheter site care
(a) Change clear dressing every 7 days unless visibly soiled, loosened, or dampened
(b) Change sterile gauze dressing every 2 days unless visibly soiled, loosened, or dampened
(c) Chlorhexidine scrub to site with dressing changes (30 second scrub followed by 30-second air-dry)
(d) No iodine ointment at site
(e) Chlorhexidine-impregnated sponge placed at insertion site with every dressing change
(f) Prepackaged dressing change kit used for all dressing changes
(3) Catheter/hub/cap/tubing care
(a) Replace continuous administration sets no more frequently than every 72 hours (no less frequently than every 96 hours), unless
visibly soiled or contaminated
(b) Replace intermittent administration sets every 24 hours or sooner if visibly soiled or contaminated
(c) Replace tubing used to administer blood, blood products, or lipids within 24 hours of initiating infusion
(d) Cap change every 7 days and within 24 hours of blood product administration (sooner if visibly soiled or contaminated)
(e) Prepackaged cap change kit
(4) Daily discussion of line necessity and integrity
the CDC recommends immunization with the tetravalent
conjugatemeningococcalvaccine,andimmunizationofado-
lescentswiththis vaccinehas becomeroutine [44].The men-
ingitis belt of sub-Saharan Africa, however, has the highest
rates of meningococcus meningitis worldwide. In this part
of the world, Group A meningococcus accounts for the vast
majority of cases and causes epidemics every 7 to 14 years
[45]. WHO therefore advocates for the introduction of a new
meningococcal A conjugate vaccine throughout more than
twodozennationsintheAfricanmeningitisbelt.Thisimmu-
nization became available in December 2010 [45]. High cov-
erage of this immunization in children and young adults
could eliminate meningococcal A from that region. As with
HIB and Streptococcus pneumoniae, immunization has be-
come a powerful tool in the prevention of overwhelming
invasive infection from meningococcus.
3.4.RefusaltoImmunize. Thoughimmunizations haveelim-
inated or reduced the incidence of many infectious diseases
that cause substantial morbidity and mortality, parental
refusal to immunize their children has become a relatively
common occurrence in the United States. Parents often cite
concerns around immunization safety for their refusal to im-
munize [46]. Because success of an immunization program
requires high coverage rates, increasing refusal to immunize
makes populations vulnerable to disease. In fact, geographic
clustering of refusals has resulted in outbreaks of vaccine-
preventable illnesses [47]. Any prevention eﬀort that utilizes
immunization must therefore recognize and manage this
signiﬁcant barrier to success.
4.Healthcare AssociatedInfections
A third strategy in the prevention of sepsis is the prevention
of healthcare-associated infections (HAIs), an area of med-
icine that has received increasing amounts of attention in
recent years. HAIs are infections that occur to patients while
they are receiving care for other conditions, and they repre-
sent the most common complication aﬀecting hospitalized
patients today, with currently 5 to 10 percent of patients in
acute care hospitals acquiring one or more infections [48].
Surgical site infections (SSI), central line-associated blood-
streaminfections(CLABSI),catheter-associatedurinarytract6 Critical Care Research and Practice
infections (CA-UTI), and ventilator-associated pneumonia
(VAP) account for the vast majority of all HAIs. These infec-
tions frequently lead to hospital-acquired sepsis and subse-
quent death. Approximately, 2 million patients experience
HAIs every year in the United States, and these infections
result in approximately 90,000 deaths. HAIs also account for
an estimated $4.5 to $5.7 billion in additional costs every
year [48]. Prevention of these infections has therefore be-
come a major priority in healthcare. In 2005, the Institute
for Healthcare Improvement launched its 100,000 Lives
Campaign, which is now the 5 Million Lives Campaign, tar-
getingpreventionandreductionofSSIs,CLABSIs,andVAPs.
As of October of 2008, the Center for Medicare and Medi-
caid Services (CMS) has stopped reimbursing hospitals for
expenses related to the treatment of certain HAIs, including
SSI, CA-BSI, VAP, and CA-UTI [49].
There is a growing body of evidence that the use of “bun-
dles” can lower the rate of certain HAIs in both hospitalized
children [50–53] and adults [54, 55]. While implementing
any one of the speciﬁc interventions in a bundle may not sig-
niﬁcantly impact the overall rate of HAIs, implementing all
of the elements in aggregate can dramatically lower the rates
of these infections. For example, the Cincinnati Children’s
Hospital Medical Center CA-BSI insertion and maintenance
bundles are shown in Table 2. Reliable and widespread im-
plementationofthesetwobundlesinalloftheinpatientunits
at our hospital resulted in a dramatic reduction in the overall
rate of CA-BSI [53, 56].
Prevention of HAIs is an important component in pre-
venting sepsis. Multimodal interventions have proven suc-
cessful at reducing HAI rates. Systematic application of evi-
dence-basedpracticesthataimtoreduceHAIsisthereforean
important and necessary part of any eﬀort to prevent sepsis.
5. Conclusions
Given the substantial toll that sepsis takes worldwide, pre-
vention of sepsis remains a global priority. Multiple eﬀective
prevention strategies exist. Antibiotic prophylaxis, immuni-
zations, and healthcare quality improvement initiatives are
important means through which we may reduce the morbid-
ity and mortality from sepsis around the world. Inclusion of
these strategies in a coordinated and thoughtful campaign
to reduce the global burden of sepsis is necessary for the
improvement of pediatric health worldwide.
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